Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Iambic to Participate in March Investor Conferences

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

IAM1363-01: A Phase 1/1b Study of a Selective and Brain-Penetrant HER2 Inhibitor for HER2-Driven Solid Tumors

Validation of a Novel Type II HER2 Inhibitor Through Preclinical Studies Across Various Cancer Models (AACR 2024 Poster)

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Entos (Now Iambic) in Collaboration with Caltech and NVIDIA: Advances in geometric deep learning for computational chemistry in Proceedings of the National Academy of Science USA

#COVIDisAirborne: AI-enabled multiscale computational microscopy of delta SARS-CoV-2 in a respiratory aerosol

JPM Healthcare Conference 2026 Company Presentation

Promise & Reality: Decoding AI’s Impact On Drug Development

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development

Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance

Predictive Drug Discovery with Enchant v2

Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25

Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum

Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite